Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy

Astha Thakkar, Kith Pradhan, Shawn Jindal, Zhu Cui, Bradley Rockwell, Akash Pradip Shah, Stuart Packer, R. Alejandro Sica, Joseph Sparano, D. Yitzhak Goldstein, Amit Verma, Sanjay Goel, Balazs Halmos

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Abstract

Patients with cancer have been identified in several studies to be at high risk of developing severe COVID-19; however, rates of SARS-CoV-2 IgG seroconversion and its association with cancer types and anticancer therapy remain obscure. We conducted a retrospective cohort study in patients with cancer who underwent SARS-CoV-2 IgG testing. Two hundred and sixty-one patients with a cancer diagnosis underwent SARS-CoV-2 IgG testing and demonstrated a high rate of seroconversion (92%). However, significantly lower seroconversion was observed in patients with hematological malignancies (82%), patients who received anti-CD-20 antibody therapy (59%) and stem cell transplant (60%). Notably, all 17 patients who received immunotherapy, including 16 that received anti-PD-1/PD-L1 monoclonal antibodies, developed SARS-CoV-2 IgG antibodies (100% seroconversion). These data show differential rates of seroconversion in specific patient groups and bear importance for clinical monitoring and vaccination strategies that are being developed to mitigate the COVID-19 pandemic.

Original languageEnglish (US)
Pages (from-to)392-399
Number of pages8
JournalNature Cancer
Volume2
Issue number4
DOIs
StatePublished - Apr 2021

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy'. Together they form a unique fingerprint.

Cite this